{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:47Z","timestamp":1792787267005,"version":"4.5.0"},"reference-count":60,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Boehringer Ingelheim The Netherlands"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,7,20]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting \u03b22 agonist\/inhaled corticosteroid (LABA\/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium\/olodaterol, tiotropium monotherapy or LABA\/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with tiotropium\/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA\/ICS. The Finnish payer\u2019s incremental cost-effectiveness ratio (ICER) of tiotropium\/olodaterol was \u20ac11 000\/QALY versus tiotropium and dominant versus LABA\/ICS. The Swedish ICERs were \u20ac6200\/QALY and dominant, respectively (societal perspective). The Dutch ICERs were \u20ac14 400 and \u20ac9200, respectively (societal perspective). The probability that tiotropium\/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA\/ICS, this probability was 100% for all three countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the simulations, tiotropium\/olodaterol is a cost-effective treatment option versus tiotropium or LABA\/ICS in all three countries. In both Finland and Sweden, tiotropium\/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA\/ICS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-049675","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T12:55:55Z","timestamp":1628081755000},"page":"e049675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness of the fixed-dose combination tiotropium\/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting \u03b22-agonist\/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-9780","authenticated-orcid":false,"given":"Martine","family":"Hoogendoorn","sequence":"first","affiliation":[{"name":"institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Corro Ramos","sequence":"additional","affiliation":[{"name":"institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Soulard","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim The Netherlands, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cook","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Soini","sequence":"additional","affiliation":[{"name":"ESiOR Oy, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Paulsson","sequence":"additional","affiliation":[{"name":"Quantify Research AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8706-3159","authenticated-orcid":false,"given":"Maureen","family":"Rutten-van M\u00f6lken","sequence":"additional","affiliation":[{"name":"institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands"},{"name":"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"2025121603251132000_11.8.e049675.1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/COPD.S150853","article-title":"Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique","volume":"13","author":"Blanco","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.2","doi-asserted-by":"crossref","first-page":"181-194","DOI":"10.1007\/s10198-019-01119-1","article-title":"The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature","volume":"21","author":"Rehman","year":"2020","journal-title":"Eur J Health Econ"},{"key":"2025121603251132000_11.8.e049675.3","unstructured":"Global Strategy for the Diagnosis . Management and prevention of COPD, global initiative for chronic obstructive lung disease (gold) report 2020, 2020. Available: http:\/\/goldcopd.org [Accessed 24 Jan 2020]."},{"key":"2025121603251132000_11.8.e049675.4","unstructured":"Global Strategy for the Diagnosis . Management and prevention of COPD, global initiative for chronic obstructive lung disease (gold) report, 2015."},{"key":"2025121603251132000_11.8.e049675.5","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S175017"},{"key":"2025121603251132000_11.8.e049675.6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S2213-2600(14)70169-9","article-title":"Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease","volume":"2","author":"Finney","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025121603251132000_11.8.e049675.7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/COPD.S95055","article-title":"The lung function profile of once-daily tiotropium and olodaterol via Respimat(\u00ae) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(\u00ae) (ENERGITO(\u00ae) study)","volume":"11","author":"Beeh","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.8","article-title":"Long-Acting muscarinic antagonist (Lama) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)","volume":"2","author":"Horita","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121603251132000_11.8.e049675.9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S130482","article-title":"LABA\/LAMA combinations versus Lama monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis","volume":"12","author":"Rodrigo","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516385"},{"key":"2025121603251132000_11.8.e049675.11","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0573-0"},{"key":"2025121603251132000_11.8.e049675.12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jval.2019.05.006","article-title":"Economic impact of reducing inappropriate inhaled corticosteroids use in patients with chronic obstructive pulmonary disease: ISPOR's guidance on budget impact in practice","volume":"22","author":"Fens","year":"2019","journal-title":"Value Health"},{"key":"2025121603251132000_11.8.e049675.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00136014"},{"key":"2025121603251132000_11.8.e049675.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.08.002"},{"key":"2025121603251132000_11.8.e049675.15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025121603251132000_11.8.e049675.16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/COPD.S191031","article-title":"Long-Term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results","volume":"14","author":"Hoogendoorn","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2147\/COPD.S114738","article-title":"Cost-Effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands","volume":"11","author":"van Boven","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.18","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816657272"},{"key":"2025121603251132000_11.8.e049675.19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/CEOR.S116546","article-title":"UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other Lama + LABA combinations in patients with COPD","volume":"8","author":"Tebboth","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025121603251132000_11.8.e049675.20","article-title":"The effect of tiotropium\/olodaterol versus tiotropium on COPD exacerbation rates in patients with\/without frequent exacerbation history","volume":"54","author":"Wedzicha","year":"2019","journal-title":"Eur Respir J"},{"key":"2025121603251132000_11.8.e049675.21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jval.2018.10.008","article-title":"Broadening the perspective of cost-effectiveness modeling in chronic obstructive pulmonary disease: a new patient-level simulation model suitable to evaluate stratified medicine","volume":"22","author":"Hoogendoorn","year":"2019","journal-title":"Value Health"},{"key":"2025121603251132000_11.8.e049675.22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/0272989X20932145","article-title":"How to address uncertainty in health economic Discrete-Event simulation models: an illustration for chronic obstructive pulmonary disease","volume":"40","author":"Corro Ramos","year":"2020","journal-title":"Med Decis Making"},{"key":"2025121603251132000_11.8.e049675.23","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.2147\/COPD.S173472","article-title":"Comparative efficacy of inhaled medications (ICS\/LABA, Lama, LAMA\/LABA and SAMA) for COPD: a systematic review and network meta-analysis","volume":"13","author":"Aziz","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.24","article-title":"Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis","volume":"12","author":"Oba","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121603251132000_11.8.e049675.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"2025121603251132000_11.8.e049675.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2613"},{"key":"2025121603251132000_11.8.e049675.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008378"},{"key":"2025121603251132000_11.8.e049675.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303342"},{"key":"2025121603251132000_11.8.e049675.29","unstructured":"Preparing a health economic evaluation to be attached to the application for reimbursement status and Wholesale price for a medicinal product. Application instructions (2019) for Finland. Available: https:\/\/www.hila.fi\/content\/uploads\/2020\/01\/Instructions_TTS_2019.pdf [Accessed Mar 2020]."},{"key":"2025121603251132000_11.8.e049675.30","unstructured":"Sweden: general guidelines for economic evaluations from the dental and pharmaceutical benefits agency (updated 2017). Available: https:\/\/www.tlv.se\/om-oss\/om-tlv\/regelverk\/allmanna-rad.html [Accessed Mar 2020]."},{"key":"2025121603251132000_11.8.e049675.31","unstructured":"Dutch guidelines: guideline for the conduct of economic evaluations in health care (Dutch version February 2016). Available: https:\/\/www.zorginstituutnederland.nl\/over-ons\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg"},{"key":"2025121603251132000_11.8.e049675.32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations","volume":"29","author":"van Baal","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"2025121603251132000_11.8.e049675.33","first-page":"118","article-title":"Terveysteknologioiden taloudellisen arvioinnin tuloksiin \u2013 esimerkkin\u00e4 i\u00e4kk\u00e4iden pneumokokkirokottaminen. perspective affects economic assessment of health technologies \u2013 using the elderly pneumococcal vaccination as example","volume":"35","author":"Mankinen","year":"2019","journal-title":"Dosis"},{"key":"2025121603251132000_11.8.e049675.34","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00810-8"},{"key":"2025121603251132000_11.8.e049675.35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090145"},{"key":"2025121603251132000_11.8.e049675.36","article-title":"Copd maintenance therapy with tiotropium\/olodaterol versus LABA\/ICS: an assessment of the risk of treatment escalation and adverse outcomes in over 40,000 patients","volume":"201","author":"Quint","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121603251132000_11.8.e049675.37","unstructured":"Drug prices 12\/2019. Helsinki: pharmaceuticals pricing board 2020."},{"key":"2025121603251132000_11.8.e049675.38","unstructured":"Official statistics of Finland: Reimbursements of medicine expenses: number of recipients and prescription data. Helsinki: Kela 2020."},{"key":"2025121603251132000_11.8.e049675.39","unstructured":"FASS . Swedish webpage containing information about all accepted drugs and related dosing information to indications. Available: https:\/\/www.fass.se\/LIF\/startpage"},{"key":"2025121603251132000_11.8.e049675.40","unstructured":"Medprice document, medical product prices downloaded from Swedish TLV \u2013 the standard for medical evaluations in Sweden. Available: https:\/\/www.tlv.se\/in-english\/prices-in-our-database.html [Accessed Apr 2020]."},{"key":"2025121603251132000_11.8.e049675.41","unstructured":"Costs and reimbursement of drugs in the Netherlands (may 2020). Zorginstituut Nederland. Available: www.medicijnkosten.nl [Accessed Apr 2020]."},{"key":"2025121603251132000_11.8.e049675.42","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1038\/npjpcrm.2015.15","article-title":"Annual costs of chronic obstructive pulmonary disease in Finland during 1996-2006 and a prediction model for 2007-2030","volume":"25","author":"Herse","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"key":"2025121603251132000_11.8.e049675.43","unstructured":"Kapiainen S , V\u00e4is\u00e4nen A , Haula T . Terveyden- JA sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2011. health and social care unit cost in Finland in 2011, 2014."},{"key":"2025121603251132000_11.8.e049675.44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/COPD.S149633","article-title":"Economic burden of COPD in a Swedish cohort: the Arctic study","volume":"13","author":"Lisspers","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.45","unstructured":"South Health Care Region, Sweden . Regionala priser och ers\u00e4ttningar f\u00f6r s\u00f6dra sjukv\u00e5rdsregionen 2020, 2020. Available: https:\/\/sodrasjukvardsregionen.se\/verksamhet\/avtal-priser\/ [Accessed Apr 2020]."},{"key":"2025121603251132000_11.8.e049675.46","unstructured":"Nivel . Leven Met EEN longziekte in Nederland Cijfers en trends over de zorg- en leefsituatie van mensen Met EEN longziekte 2018, 2019."},{"key":"2025121603251132000_11.8.e049675.47","unstructured":"Transparante ketenzorg . Rapportage 2018. Zorggroepen diabetes mellitus, VRM, COPD en astma. Ineen 2019."},{"key":"2025121603251132000_11.8.e049675.48","unstructured":"Hakkaart-van Roijen L , Van der Linden N , Bouwmans CAM . Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. (Dutch costing manual) Zorginstituut Nederland. Geactualiseerde versie, 2015."},{"key":"2025121603251132000_11.8.e049675.49","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2147\/COPD.S222581","article-title":"The burden of chronic obstructive pulmonary disease (COPD) in Finland: impact of disease severity and eosinophil count on healthcare resource utilization","volume":"14","author":"Viinanen","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.50","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2147\/COPD.S144571","article-title":"Estimating the effectiveness of pulmonary rehabilitation for COPD exacerbations: reduction of hospital inpatient days during the following year","volume":"12","author":"Katajisto","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121603251132000_11.8.e049675.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.10.007"},{"key":"2025121603251132000_11.8.e049675.52","unstructured":"Zorgstandaard COPD 2019. Long Alliantie Nederland."},{"key":"2025121603251132000_11.8.e049675.53","unstructured":"Influenssarokotuskattavus, Kausi 2018-2019 : 65 v t\u00e4ytt\u00e4neet. Influenza vaccination allowance, Season 2018-2019 : 65 years of age. RokottaminenRokotusrekisteri. 2020."},{"key":"2025121603251132000_11.8.e049675.54","unstructured":"Andel AV befolkningen \u226565 \u00e5r vaccinerad mot influensa, s\u00e4song 2018\u20132019. proportion of the population \u226565 years vaccinated against influenza, season 2018-2019. Available: https:\/\/www.folkhalsomyndigheten.se\/contentassets\/fd95add32f77479bac3ca61934527008\/vaccinationstackningen-influensa-2018-2019.pdf [Accessed Apr 2020]."},{"key":"2025121603251132000_11.8.e049675.55","unstructured":"Monitor Vaccinatiegraad Nationaal Programma Grieppreventie 2018."},{"key":"2025121603251132000_11.8.e049675.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2004.12.008"},{"key":"2025121603251132000_11.8.e049675.57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/02813432.2015.1114352","article-title":"Primary-care-based episodes of care and their costs in a three-month follow-up in Finland","volume":"33","author":"Heinonen","year":"2015","journal-title":"Scand J Prim Health Care"},{"key":"2025121603251132000_11.8.e049675.58","unstructured":"Average monthly wages in 2018, for those who worked. statistics Sweden, 2018."},{"key":"2025121603251132000_11.8.e049675.59","unstructured":"Average number of inpatient days by ICD-10 code. statistics Sweden, 2018."},{"key":"2025121603251132000_11.8.e049675.60","unstructured":"Hospital admissions by ICD-10 code. statistics Netherlands 2017."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-049675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:25:22Z","timestamp":1765884322000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-049675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,4]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bmjopen-2021-049675"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-049675","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}